Completed PHASE3 NCT02302716

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study

Sponsor: Boehringer Ingelheim

Conditions Diabetes Mellitus, Type 2

Interventions LANTUS® LY2963016 Oral Antihyperglycemic Medication

Updated 8 times since 2017 Last updated: Sep 25, 2017 Started: Dec 31, 2014 Primary completion: Jul 31, 2016 Completion: Jul 31, 2016

This PHASE3 trial investigates Diabetes Mellitus, Type 2 and is currently completed. Boehringer Ingelheim leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 3 earlier versions

Nov 2017 — Jun 2018 [monthly]

Completed PHASE3
Feb 2017 — Nov 2017 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim
Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ahmedabad, India , Ankara, Turkey (Türkiye) , Ansan-si, South Korea , Antalya, Turkey (Türkiye) , Bucheon-si, South Korea , Chattanooga, United States , Cheboksary, Russia , Chennai, India , Columbus, United States , Daegu, South Korea and 32 more locations